Gilead buying another NASH program for up to $470m
This article was originally published in Scrip
Executive Summary
Gilead Sciences has two market-leading drugs to treat hepatitis C and now the company is expanding its liver disease empire with the acquisition of small molecules for the treatment of non-alcoholic steatohepatitis (NASH) from Phenex Pharmaceuticals.
You may also be interested in...
Gilead Pays Phenex $100m Milestone As NASH Candidate Progresses
With hepatitis C wrapped up, NASH is becoming the focus of liver disease R&D. Gilead, which has a number of NASH programs, has paid Phenex $100m for clinical progress with an in-licensed candidate for NASH and other liver diseases.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.